All In Biotech

Drug Trial Radar · NCT06962800

A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)

An Open-Label, Multicenter, Randomized Phase 3 Study Evaluating the Efficacy and Safety of Felzartamab in Participants With Primary Membranous Nephropathy (PMN) [PROMINENT]

Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 180 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

180

Planned (sponsor's estimate)

Start

May 22, 2025

Primary completion

Jan 28, 2030

Study completion Jan 17, 2031

Sponsor

Lead sponsor
BiogenBiogen (BIIB)
Sponsor type
Industry
First posted
May 8, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In this study, researchers will learn more about the use of felzartamab in participants with primary membranous nephropathy, also known as PMN. In people with PMN, autoantibodies build up in the glomeruli of the kidney. Antibodies are proteins that help the body fight off infection. An autoantibody is a type of antibody that mistakenly targets and attacks the body's own tissues. Glomeruli are the filters of the kidney that remove waste and extra fluid from the body. In PMN, the build-up of autoantibodies in the glomeruli causes damage to the kidneys. Kidney damage can lead to too much protein and blood leaking into the urine. High levels of protein in the urine, called proteinuria, are common in people with PMN. Symptoms of PMN can include swelling in the legs and body, tiredness, and high blood pressure. If left untreated, PMN can eventually lead to kidney failure. In this study, researchers will learn more about how a study drug called felzartamab affects people with PMN. Felzartamab is a monoclonal antibody, which means it is an antibody made in a laboratory. Felzartamab can target immune cells that produce autoantibodies, helping to lower their buildup in the kidneys. The main goal of this study is to compare how felzartamab works compared to a drug called tacrolimus. Tacrolimus is another drug given to people with PMN and kidney disease. The main question that researchers want to answer is: * How many participants achieve a complete response after 104 weeks of treatment? * A complete response means that their urine protein levels decrease to a low level and their kidney function remains stable. Researchers will also learn about: * How long it takes before the participants' disease gets worse * How long the participants' urine protein levels stay low * How many participants develop antibodies against felzartamab in the blood? * How many participants achieve a complete response after 76 weeks of treatment * How many participants have medical problems during the study * How felzartamab is processed by the body * How felzartamab affects participants' tiredness and overall physical health The study will be done as follows: * Participants will be screened to check if they can join the study. This may take up to 42 days. * Participants will be randomized to receive either felzartamab as intravenous (IV) infusions or tacrolimus, taken orally as tablets. * If participants have worsening kidney function or worsening proteinuria, or if their PMN relapses, or if they show no signs of improvement in their PMN, they will have a chance to receive rescue treatment. * If a participant stops treatment early, there will be follow-up visits every 12 weeks until they reach Week 104. * In total, participants will have up to 23 study visits. Participants who do not need rescue treatment will stay in the study for up to 104 weeks. Participants who need rescue treatment will stay in the study for up to 156 weeks.

Conditions

  • Primary Membranous Nephropathy

Interventions

  • FelzartamabDrug

    Administered intravenously

  • TacrolimusDrug

    Administered orally

  • Standard of Care ISTDrug

    Administered intravenously and orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants who Achieve Complete Remission (CR) at Week 104Time frame: Week 104

Locations

117 sites in 11 countries. Site status is shown where the registry gives one.

  • Apogee Clinical Research, LLC

    Huntsville, Alabama · Recruiting

  • The Nephrology Group, Inc. - Fresno

    Fresno, California · Recruiting

  • Academic Medical Research Institute

    Los Angeles, California · Recruiting

  • UCLA Health Connie Frank Kidney Transplant Center and General Nephrology

    Los Angeles, California · Recruiting

  • UCSF Medical Center

    San Francisco, California · Recruiting

  • Stanford University

    Stanford, California · Recruiting

  • Henry Ford Hospital- A-Basement Research Pharmacy

    Detroit, Michigan · Recruiting

  • Elixia Health - Michigan Kidney Consultants, LLC - Elixia - PPDS

    Pontiac, Michigan · Completed

  • James J Peters Veterans Administration Medical Center - NAVREF - PPDS

    The Bronx, New York · Recruiting

  • ECU Physicians Nephrology and Hypertension

    Greenville, North Carolina · Recruiting

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio · Recruiting

  • Knoxville Kidney Center, PLLC

    Knoxville, Tennessee · Recruiting

  • Vanderbilt University Medical Center

    Nashville, Tennessee · Recruiting

  • Nephrotex Research Group

    Dallas, Texas · Recruiting

  • University of Texas Medical Branch

    League City, Texas · Recruiting

  • University of Wisconsin School of Medicine and Public Health

    Madison, Wisconsin · Recruiting

  • Organización Médica de Investigación

    Buenos Aires, Argentina · Recruiting

  • CINME S.A. - Centro de Investigaciones Metabólicas

    Buenos Aires, Argentina · Recruiting

  • Hospital Italiano de Buenos Aires

    Buenos Aires, Argentina · Recruiting

  • Centro Medico Dra. Laura Maffei- Investigacion Clinica Aplicada

    Buenos Aires, Argentina · Recruiting

  • Clínica Privada Vélez Sarsfield

    Córdoba, Argentina · Recruiting

  • Concord Hospital

    Concord, New South Wales, Australia · Recruiting

  • St George Hospital

    Kogarah, New South Wales, Australia · Recruiting

  • Liverpool Hospital

    Liverpool, New South Wales, Australia · Recruiting

  • Westmead Hospital

    Westmead, New South Wales, Australia · Recruiting

  • Townsville Hospital

    Douglas, Queensland, Australia · Recruiting

  • Royal Brisbane and Women s Hospital

    Herston, Queensland, Australia · Recruiting

  • Gold Coast University Hospital

    Southport, Queensland, Australia · Recruiting

  • Griffith University Clinical Trial Unit

    Southport, Queensland, Australia · Recruiting

  • Monash Health

    Clayton, Victoria, Australia · Recruiting

  • Sunshine Hospital - Australia

    St Albans, Victoria, Australia · Recruiting

  • Hospital Alemao Oswaldo Cruz (HAOC)

    São Paulo, Brazil · Recruiting

  • Centro de Pesquisa Clínica de Nefrologia do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo

    São Paulo, Brazil · Recruiting

  • Santa Casa de Misericórdia de Belo Horizonte

    Belo Horizonte, Minas Gerais, Brazil · Recruiting

  • Hospital de Clinicas de Porto Alegre

    Porto Alegre, Rio Grande do Sul, Brazil · Recruiting

  • Hospital Sao Lucas Da Pontificia Universidade Catolica Do Rio Grande Do Sul (PUCRS)

    Porto Alegre, Rio Grande do Sul, Brazil · Recruiting

  • Hospital das Clinicas da Faculdade de Medicina de Ribeirao Preto da Universidade de Sao Paulo

    Ribeirão Preto, São Paulo, Brazil · Recruiting

  • Fundacao Faculdade Regional de Medicina de Sao Jose Do Rio Preto Hospital de Base - PPDS

    São José do Rio Preto, São Paulo, Brazil · Recruiting

  • Vancouver Coastal Health Research Institute

    Vancouver, British Columbia, Canada · Recruiting

  • London Health Sciences Centre - Victoria Hospital

    London, Ontario, Canada · Recruiting

Showing 40 of 117 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.